ROVI’s ESG aspects have been evaluated by Sustainalytics, a Global Leader in ESG & Corporate Governance, obtaining an “ESG Risk Rating 2020” of 18.4, which places the company at low risk (between 10 and 20). This rating is 3.4 points higher than the previous year’s rating (21.8), when the company reached a medium risk position (between 20 and 30 points).

ROVI attains the second position out of 432 companies in the sub-industry “pharmaceuticals” and 17th out of a total of 896 companies in the “pharmaceutical industry”, which includes biotech, pharmaceutical and laboratory equipment companies.